NED Biosystems Inc

NED Biosystems Inc. is a privately held company based in Cambridge, Massachusetts. The company employs 11 people and generates $2.5 million in annual revenue. NED Biosystems develops and commercializes "systems" treatments for complex diseases, starting with cancer and expanding to infectious diseases. Their flagship product, NED-170, is a patented treatment for cancer that utilizes repurposed, oral agents to target critical disease-driver processes. NED-260, developed in response to the pandemic, is a universal antiviral treatment designed to protect against a broad range of viruses. NED Biosystems distinguishes itself through its systems-based approach to treatment, which focuses on addressing the entire biological system rather than isolated components. This approach aims to provide more comprehensive and effective treatments with fewer side effects compared to traditional methods. For more information, visit nedbiosystems.com.